Nonalcoholic fatty liver disease and chronic kidney disease: random connections or two manifestations of metabolic syndrome?
https://doi.org/10.31146/1682-8658-ecg-228-8-123-130
Abstract
Non-alcoholic fatty liver disease (NAFLD) and chronic kidney disease (CKD) are two global public health problems that affect almost 30% and up to ~10-15%, respectively, of the general adult population in many parts of the world. It is quite obvious that NAFLD is a “multisystem disease” associated not only with impaired liver function and the development of hepatocellular carcinoma, but also with an increasing risk of developing cardiovascular diseases (the main cause of death in such patients), chronic kidney disease (CKD). However, the mechanisms underlying this association remain largely unknown. The aim of this review is to report on the epidemiology and pathophysiology of the relationship between NAFLD and CKD and to describe the different methods of kidney function assessment in patients with NAFLD as well as to discuss the potential for promising pharmacotherapy with simultaneous benefit for the outcomes of both diseases.
About the Authors
O. V. Khlynova
Perm State Medical University named after E. A. Wagner
Russian Federation
Russian Federation
N. S. Karpunina
Perm State Medical University named after E. A. Wagner
Russian Federation
Russian Federation
References
1. Bilson J., Mantovani A., Byrne C. D. et al. Steatotic liver disease, MASLD and risk of chronic kidney disease. Diabetes Metab. 2024; Jan;50(1): 101506. doi: 10.1016/j.diabet.2023.101506.
2. Byrne C. D., Targher G. NAFLD as a driver of chronic kidney disease. Journal of Hepatology. 2020; vol.72j:785-801. doi: 10.1016/j.jhep.2020.01.013.
3. Chulkov V. S., Pankova E. D., Krasnopeeva N. D. et al. Nonalcoholic Fatty Liver Disease, cardiovascular system and kidney status in young people. South-Russian journal of therapeutic practice. 2023;4(3):15-21. (In Russ.) doi: 10.21886/2712-8156-2023-4-3-15-21.
4. Mantovani A., Lombardi R., Cattazzo F. et al. MAFLD and CKD: An Updated Narrative Review. A.Int J Mol Sci. 2022; Jun 23;23(13):7007. doi: 10.3390/ijms23137007.
5. Umbro I., Baratta F., Angelico F. et al. Nonalcoholic Fatty Liver Disease and the Kidney: A Review. Biomedicines. 2021; 9, 1370. doi: 10.3390/biomedicines9101370.
6. Takahashi S., Tanaka M., Furuhashi M. Fatty liver index is independently associated with deterioration of renal function during a 10-year period in healthy subjects. Sci Rep. 2021; 11, 8606. doi: 10.1038/s41598-021-88025-w.
7. Krasner Ya.A., Osipenko M. F., Holin S. I. et al. Chronic Kidney Disease and Nonalcoholic Fatty Liver Disease - novel pathogenetic interactions. Experimental and Clinical Gastroenterology. 2023;212(4): 140-144. (In Russ.) doi: 10.31146/1682-8658-ecg-212-4-140-144.@@ Краснер Я. А., Осипенко М. Ф., Холин С. И., Литвинова Н. В. Хроническая болезнь почек и неалкогольная жировая болезнь печени - новые патогенетические взаимосвязи. Экспериментальная и клиническая гастроэнтерология. 2023;(4):140-144. doi: 10.31146/1682-8658-ecg-212-4-140-144.
8. Clinical guidelines of Health Ministry of Russian Federation “Nonalcoholic Fatty Liver Disease”, 2022. (In Russ.)@@ Клинические рекомендации Министерства здравоохранения Российской Федерации «Неалкогольная жировая болезнь печени у взрослых», 2022 год.
9. Ivashkin V. T., Maevskaya M. V., Zharkova M. S. et al. Clinical guidelines of Russian Society of Liver Investigation, Russian Gastroenterology Association, Russian Association of Endocrinologists, Russian Association of gerontologists and geriatric specialists and National society of preventive cardiology on diagnostics and management of nonalcoholic fatty liver disease.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(4):104-140. (In Russ.) doi: 10.22416/1382-4376-2022-32-4-104-14.@@ Ивашкин В. Т., Маевская М. В., Жаркова М. С. и др. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российской ассоциации эндокринологов, Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии по диагностике и лечению неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(4):104-140. doi: 10.22416/1382-4376-2022-32-4-104-14.
10. Maevskaya M.V., Kotovskaya Yu.V., Ivashkin V. T. et al. National Consensus for Doctors about the management of adult patients with nonalcoholic fatty liver disease and its common comorbidities. Therapeutic Archive. 2022;94(2):216-253. (In Russ.) doi: 10.26442/00403660.2022.02.201363.@@ Маевская М. В., Котовская Ю. В., Ивашкин В. Т. и др. Национальный Консенсус для врачей по ведению взрослых пациентов с неалкогольной жировой болезнью печени и ее основными коморбидными состояниями. Терапевтический архив. 2022;94(2):216-253. doi: 10.26442/00403660.2022.02.201363.
11. Tanaka M., Mori K., Takahashi S. et al. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease. Nephrol Dial Transplant. 2023; Feb 28;38(3):700-711. doi: 10.1093/ndt/gfac188.
12. Roderburg C., Krieg S., Krieg A. et al. Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD). European Journal of Medical Research. 2023;28:153. doi: 10.1186/s40001-023-01114-6.
13. Cai X., Sun L., Liu X. Non-alcoholic fatty liver disease is associated with increased risk of chronic kidney disease. Therapeutic Advances in Chronic Disease. 2021;12. doi:10.1177/20406223211024361.
14. Hydes T. J., Kennedy O. J., Buchanan R. et al. The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank. BMC Medicine. 2023;21:185. doi: 10.1186/s12916-023-02891-x.
15. Li Y., Wu Sh., Gao J. et al. Association of Stroke With Metabolic Dysfunction-Associated Fatty Liver Disease With and Without CKD. Am J Kidney Dis. 2024; Apr;83(4):477-488. doi: 10.1053/j.ajkd.2023.08.016.
16. Terasaka Y., Takahashi H., Amano K. et al. Change in Liver Fibrosis Associates with Progress of Diabetic Nephropathy in Patients with Nonalcoholic Fatty Liver Disease. Nutrients. 2023; 15(14):3248. doi: 10.3390/nu15143248.
17. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease. HepatoBiliary Surg Nutr. 2023;12(3):386-403. doi: 10.21037/hbsn-22-421.
18. Gao J., Li Y., Zhang Y. et al. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence. J Am Heart Assoc. 2024;13: e032604. doi: 10.1161/JAHA.123.032604.
19. Onwuzo S. S., Hitawala A. A., Boustany A. et al. Prevalence of non-alcoholic fatty liver disease in patients with nephrotic syndrome: A population-based study. World J Hepatol. 2023; 15(2): 265-273. doi: 10.4254/wjh.v15.i2.265.
20. Lee H. H., Ro H., Jung J. Y. et al. The Fatty Liver Index’s Association with Incident Chronic Kidney Disease in Korean Middle-Aged Adults: A Community-Based Cohort Study. J. Clin. Med. 2024;13:1616. doi: 10.3390/jcm13061616.
21. Navadurong H., Prasoppokakorn T., Srisawat N. Urinary neutrophil gelatinase-associated lipocalin: a novel biomarker for predicting chronic kidney disease in patients with nonalcoholic fatty liver disease. Port Hypertens Cirrhos. 2022;1:157-166. doi:10.1002/poh2.32.
22. Lonardo A. Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review. Metab Target Organ Damage. 2024;4:16. doi: 10.20517/mtod.2024.07.
23. Sun D. Q., Jin Y., Wang T. Y. et al. MAFLD and risk of CKD. Metabolism Clinical and Experimental. 2021; 154433. doi: 10.1016/j.metabol.2020.154433.
24. Kiapidou S., Liava C., Kalogirou M. et al. Chronic kidney disease in patients with non-alcoholic fatty liver disease: What the Hepatologist should know? Annals of Hepatology. 2020; 134-144. doi: 10.1016/j.aohep.2019.07.013.
25. Yodoshi T., Arce-Clachar A.C., Sun Q. et al. Glomerular Hyperfiltration Is Associated with Liver Disease Severity in Children with Nonalcoholic Fatty Liver Disease. The Journal of Paediatrics. 2020; vol. 222, pp. 127-133. doi: 10.1016/j.jpeds.2020.03.038.
26. Mima A. Prediction of decreased estimated glomerular filtration rate using liver fibrosis markers: a renal biopsy-based study. Sci Rep. 2022; 12, 17630. doi: 10.1038/s41598-022-22636-9.
27. Tao Z., Li Y., Cheng B. et al. Influence of Nonalcoholic Fatty Liver Disease on the Occurrence and Severity of Chronic Kidney Disease. J Clin Transl Hepatol. 2022;10(1):164-173. doi: 10.14218/JCTH.2021.00171.
28. Hassouneh R., Siddiqui M. S., Bhati C. Risk of cardio-nephro-metabolic disease from NAFLD to MAFLD: fact or fiction? Metab Target Organ Damage. 2021;1:4. doi: 10.20517/mtod.2021.07.
29. Rinella M. E., Brent N.-T., Shadab S. М. et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5): p 1797-1835, May 2023. doi: 10.1097/HEP.0000000000000323.
30. Miyamori D., Tanaka M., Sato T. et al. Coexistence of Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease Is a More Potent Risk Factor for Ischemic Heart Disease. J Am Heart Assoc. 2023 Jul 18;12(14): e030269. doi: 10.1161/JAHA.123.030269.
31. Pan B., Wan X., Ma M. et al.Complement C3 and Nonalcoholic Fatty Liver Disease in Chronic Kidney Disease Patients: A Pilot Study. Kidney Blood Press Res. 2020;45:61-69.
32. Dahiya Sh., Kulkarni V., Gupta T. et al. Prevalence and Severity of Non-Alcoholic Fatty Liver Disease in Patients with Chronic Kidney Disease. JIACM. 2023; 24 (2): 91-97.
33. Heda R., Yazawa M., Shi M. et al. Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. World J Gastroenterol. 2021; 27(17): 1864-1882. doi: 10.3748/wjg.v27.i17.1864.
34. Tang L-J., Sun D-Q., Song S. J. Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort. Liver Int. 2024; 44: 1129-1141. doi: 10.1111/liv.15878.
35. Drapkina O. M., Zyatenkova E. V. Kidney injury in patients with nonalcoholic fatty liver disease and chronic heart failure. Medical Council. 2015;(13): 118-123. (In Russ.)@@ Драпкина О. М., Зятенкова Е. В. Поражение почек у пациентов с неалкогольной жировой болезнью печени и хронической сердечной недостаточностью. Медицинский совет. 2015;(13): 118-123.
36. Stacenko M.E., Turkina S. V., Ermolenko A. A. et al. Nonalcoholic fatty liver disease - new risk factor of chronic kidney disease. Herald of VolGMU. 2018; № 2 (66). (In Russ.) Available at: https://cyberleninka.ru/article/n/nealkogolnaya-zhirovaya-bolezn-pecheni-novyy-faktor-riska-razvitiya-hronicheskoy-bolezni-pochek (Accessed: 29.04.2024).@@ Стаценко М. Е., Туркина С. В., Ермоленко А. А. и др. Неалкогольная жировая болезнь печени - новый фактор риска развития хронической болезни почек. Вестник ВолГМУ. 2018; № 2 (66). URL: https://cyberleninka.ru/article/n/nealkogolnaya-zhirovaya-bolezn-pecheni-novyy-faktor-riska-razvitiya-hronicheskoy-bolezni-pochek (дата обращения: 29.04.2024).
37. Shelihovskaya P.A., Sabirova A. I., Mamytova A. B. Nephrotic and cerebrovascular risks in nonalcoholic fatty liver disease. Тhe Scientific Heritage. 2020;46-3(46): 71-76. (In Russ.)@@ Шелиховская П. А., Сабирова А. И., Мамытова А. Б. Нефротические и цереброваскулярные риски при неалкогольной жировой болезни печени. Тhe Scientific Heritage. 2020;46-3(46): 71-76.
38. Cao Y., Du Y., Jia W. et al. Identification of biomarkers for the diagnosis of chronic kidney disease (CKD) with non-alcoholic fatty liver disease (NAFLD) by bioinformatics analysis and machine learning. Front. Endocrinol. 2023;14:1125829. doi: 10.3389/fendo.2023.1125829.
39. Baratta F., D’Erasmo L., Di Costanzo A. et al. Metabolic Syndrome but Not Fatty Liver-Associated Genetic Variants Correlates with Glomerular Renal Function Decline in Patients with Non-Alcoholic Fatty Liver Disease. Biomedicines. 2022; 10(3):720. doi: 10.3390/biomedicines10030720.
40. Xuezhu L., Dipankar B., Yue Y. Chronic kidney disease in a murine model of non-alcoholic steatohepatitis (NASH). Basic Research. 2024; Vol. 105, (3): 540-561. doi: 10.1016/j.kint.2023.12.009.
41. Hu H., Cao C., Han Y. et al. Triglyceride affects the association between estimated glomerular filtration rate and the onset of non-alcoholic fatty liver disease: A second analysis of a Chinese cohort study. Front. Med. 2022;9:984241. doi: 10.3389/fmed.2022.984241.
42. Yang M., Geng C. A., Liu X. et al. Lipid Disorders in NAFLD and Chronic Kidney Disease. Biomedicines. 2021; Oct 6;9(10):1405. doi: 10.3390/biomedicines9101405.
43. Bock F., Al-Dabet Moh’d Mohanad A., Shahzad K. et al. The Effect of Ursodiol on Kidney Function: A Retrospective Case Series of Patients with Diabetic Kidney Disease. 2017; https://www.asn-online.org/education/kidneyweek/2017/program-abstract.aspx?controlId=2783116.
44. Yang Y., Liu S., Gao H. et al. Ursodeoxycholic acid protects against cisplatin-induced acute kidney injury and mitochondrial dysfunction through acting on ALDH1L2. Free Radical Biology and Medicine. 2020;152: 821-837.
45. Yakovleva S. V., Pirogova I. Yu. Relationship between cardiometabolic risk factors and 25(OH)D levels in young men with non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2022;(10):50-57. (In Russ.) doi: 10.31146/1682-8658-ecg-206-10-50-57.@@ Яковлева С. В., Пирогова И. Ю. Взаимосвязь кардиометаболических факторов риска и уровня 25(ОН)Д у молодых мужчин на фоне неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. 2022;(10):50-57. doi: 10.31146/1682-8658-ecg-206-10-50-57.
46. Gouni- Berthold I., Berthold H. K. Vitamin D and Vascular Disease. Curr Vasc Pharmacol. 2021;19(3):250-268. doi: 10. 2174/1570161118666200317151955.
47. Raj D., Tomar B., Lahiri A. et al. The gut-liver-kidney axis: Novel regulator of fatty liver associated chronic kidney disease. Pharmacological Research. 2020; 152:104617. doi: 10.1016/j.phrs.2019.104617.
48. Grander C., Grabherr F., Tilg H. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. Cardiovascular Research. 2023;119,9: 1787-1798. doi: 10.1093/cvr/cvad095.
Review
For citations:
Khlynova O.V., Karpunina N.S. Nonalcoholic fatty liver disease and chronic kidney disease: random connections or two manifestations of metabolic syndrome? Experimental and Clinical Gastroenterology. 2024;(8):123-130. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-228-8-123-130
Views:
1461
Email this article 